Waters Corporation and Labcorp have announced a partnership to expand access to the FDA-approved BD Onclarity HPV Assay through Labcorp’s nationwide laboratory network, with availability planned by the end of 2026. The collaboration aims to address gaps in cervical cancer screening by offering clinician-collected and self-collected testing options across clinical settings, patient service centers, and at-home channels.
Cervical cancer is largely preventable through routine screening and early detection of human papillomavirus (HPV), yet millions of women remain overdue for recommended testing, according to the announcement. Adding to these concerns, the proportion of US women who have never undergone cervical cancer screening has increased substantially in recent years, particularly among women aged 21 to 29.
The expanded screening options are intended to help reach people who face barriers related to privacy, access, and socioeconomic circumstances.
Labcorp serves more than 850,000 physicians and healthcare providers and operates more than 2,200 patient service centers. The company plans to offer the testing options through clinician programs, health plan Gaps in Care programs, and consumer channels, including Labcorp OnDemand.
“Barriers such as privacy, access, and socioeconomic factors can make it difficult to stay current with cervical cancer screening,” said Jeff Andrews, MD, FRCSC, vice president of Medical Affairs, Waters Advanced Diagnostics, Waters Corporation. “We are at the start of a new era in which screening can extend beyond the clinic, enable more personalized risk assessment, and reach people who have historically been underserved. By offering greater flexibility in how and where people are screened, our collaboration marks a critical step forward in bridging one of today’s most profound care gaps.”
Extended genotyping supports risk assessment
The BD Onclarity HPV Assay is the only FDA-approved HPV test that supports all American Society for Colposcopy and Cervical Pathology (ASCCP) Enduring Risk-Based Management Guidelines, according to Waters and Labcorp.
Certain HPV genotypes, including types 16, 18, and 45, are associated with increased cervical cancer risk, making genotype-specific information important for patient management. The assay individually identifies six high-risk HPV types—16, 18, 31, 45, 51, and 52—and provides results for three additional strategically pooled groups. The company states that this extended genotyping capability is available regardless of the specimen collection method.
The announcement also highlights changes in the distribution of high-risk HPV infections. As HPV vaccination has reduced infections from types 16 and 18, other high-risk HPV strains account for a growing share of cervical disease, particularly among younger, vaccinated populations. Extended genotyping can provide more detailed information about the HPV types detected to help inform clinical management.
“Cervical cancer screening saves lives, but too many women still face barriers to getting screened,” said Dr. Brian Caveney, chief medical and scientific officer, Labcorp. “By expanding access and options for comprehensive FDA-approved HPV testing, we can help more women stay current with recommended screening, reach those who may be overdue for care, and support earlier identification of cervical cancer risk.”
The BD Onclarity HPV Assay is expected to become available through Labcorp by the end of 2026.
This article was created with the assistance of Generative AI and has undergone editorial review before publishing.





